ICAR-CIPHET licenses groundnut-based products for health-conscious consumers
The product portfolio for Nectar ranges from essential anti-diabetic formulations to combination medications, offering comprehensive solutions for Type 2 diabetes management
Nectar Life Care has announced the launch of a new range of high-quality, cost-effective anti-diabetic formulations, with Dapagliflozin under the brand name DAPNEC. With the expiration of API patents, these medicines will now be available at affordable prices, enhancing accessibility while maintaining high efficacy.
India, often called the ‘Diabetes Capital of the World,’ faces a rising demand for effective diabetes management solutions. Type 2 diabetes, once prevalent among adults, is now increasingly affecting younger individuals due to sedentary lifestyles, poor dietary habits, and rising obesity rates. According to the Indian Council of Medical Research (ICMR), over 77 million people in India have diabetes, with a significant portion undiagnosed. Studies by the Indian Diabetes Risk Score (IDRS) indicate that more than 10 per cent of urban Indian youth are at risk, underscoring the need for comprehensive and accessible healthcare solutions.
The product portfolio for Nectar ranges from essential anti-diabetic formulations to combination medications, offering comprehensive solutions for Type 2 diabetes management as prescribed by the physician. The range also includes:
• SITANEC M 50/500 & 50/1000 – Metformin and Sitagliptin Tablets
• METNEC-G1 & METNEC G2 – Metformin and Glimepiride Tablets
• METNEC 500mg – Metformin Tablets
Manufactured in a WHO-GMP-certified facility, the range is designed to meet international quality standards while ensuring affordability. The company reported Rs 6.4 crore in sales last year and is anticipating crossing the Rs 15 crore mark this year with the introduction of its diabetes care portfolio. This expansion strengthens Nectar Lifecare’s presence in both domestic and international markets, reinforcing its position as a trusted partner for pharmaceutical distributors, exporters, and healthcare providers.